Introduced
by
To impose a new mandate on manufacturers of prescription drugs that they must file detailed reports with a state agency on the costs associated with developing and marketing certain prescription drugs.
Referred to the Committee on Health Policy
Reported without amendment
Refer to the Committee on Ways and Means with the recommendation that the substitute (H-1) be adopted.
Referred to the Committee on Ways and Means
